ValiRx Share News (VAL)

ValiRx Anti-Cancer Compound To Undergo Further Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that its clinical trial project team for its anti-cancer compound VAL201 has recommended a further stability and sterility study to allow for the acceleration towards a Phase 2 efficacy study. ValiRx said it had accepted the advice of the tea

ValiRx Loss Widens As It Ups Investment In Clinical Trial Programme

LONDON (Alliance News) - Biotechnology company ValiRx PLC Wednesday posted a widened pretax loss in 2013 as revenue declined, and it upped investment in the clinical trial programme for its anti-cancer therapeutic VAL201. The company posted a pretax loss of GBP2.9 million, widened from GBP2

ValiRx Biomarket Receives European Patent Approval

LONDON (Alliance News) - ValiRx PLC Thursday said a cancer screening test gene biomarker called NAV3, acquired by its subsidiary in 2012, has received patent approval from the European Patent Office. In a statement, ValiRx said the latest approval means it has biomarker patent protection in

ValiRx Sells Shares In VolitionRx For USD601,578

LONDON (Alliance News) - ValirRx PLC Friday said it has sold its shareholding in VolitionRx to an unnamed firm for USD601,578 and will use the proceeds for the continuing clinical development of its anti-cancer therapeutics VAL101 and VAL201. The life science company had 510,811 shares in c

ValiRx Raises GBP2.9 Million In Placing To Fund Oncology Work

CORRECT: AIM IN BRIEF: Herstal Emerges As Favourite To Acquire Manroy

AIM IN BRIEF: Beretta Emerges As Favourite To Acquire Manroy

CORRECT: ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

UK WINNERS & LOSERS: IAG Dives Despite Raising Profit Guidance

ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

AIM IN BRIEF: Quindell And ValiRx Placings; Noricum Gold Positive Results

ValiRx Anti-Cancer Treatment Advances To Phase 2 Of Clinical Trial

UK WINNERS & LOSERS: Phorm Jumps; Supermarkets Rebound

ValiRx Cancer Treatment Files Escalation Study

ValiRX reports encouraging progress despite losses

ValiRx, a biopharmaceutial company with a focus on the treatment of cancer, said while losses had widened in the first half it had made "excellent" advances in its clinical and pre-clinical development pipeline. It reiterated that it expected results from the first stage of clinical trials for its